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Venous thromboembolism (VTE) in children is multifactorial and most often related to a 
combination of inherited and acquired thrombophilias. Children with cancer and blood 
disorders are often at risk for VTE due to disease-related factors such as inflammation 
and abnormal blood flow and treatment-related factors such as central venous cathe-
ters and surgery. We will review risk factors for VTE in children with leukemia, lymphoma, 
and solid tumors. We will also review risk factors for VTE in children with blood disorders 
with specific focus on sickle cell anemia and hemophilia. We will present the available 
evidence and clinical guidelines for prevention and treatment of VTE in these populations.
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venOUS THROMBOeMBOLiSM in CHiLDRen wiTH CAnCeR
Venous thromboembolism (VTE) including deep venous thrombosis (DVT) and pulmonary embo-
lism (PE) result in significant morbidity and mortality in individuals with cancer. VTE is a leading 
cause of death in adults with cancer (1). As care for critically ill children improves, the incidence of 
VTE in children is increasing (2). The general incidence of VTE in children ranges from 0.7 to 1.4 
VTE/100,000 children and 53 VTE/100,000 hospital admissions (3–5). Children with cancer make 
up one of the largest subsets of patients who experience VTE (2). A study using the 1994–2009 
Nationwide Inpatient Samples identified cancer as one of the primary risk factors for pediatric VTE-
related hospital admissions (6). Other identified risk factors, central venous catheter (CVC) use, 
mechanical ventilation, and hospitalization of >5 days are common in this population.
VTE occurs in 2.1–16% of children with cancer (7–10). Rates vary based on the diagnostic 
imaging modality and whether VTE is symptomatic or asymptomatic. The rate is higher when 
patients who were screened for asymptomatic VTE are included (10, 11). Walker et al. conducted a 
population-based cohort study in the United Kingdom to compare rates of VTE between children 
with and without cancer. In this study, the absolute rate of VTE in children with cancer was 1.52 per 
1,000 person-years (95% CI = 0.57–4.06) versus 0.06 per 1,000 person-years (95% CI = 0.02–0.15) 
in controls without cancer [hazard ratio of 28.3 (95% CI = 7.0–114.5)] (12).
The occurrence of VTE varies by cancer type (12). In a population-based cohort study utilizing 
national databases in the UK, the rate of VTE per 1,000 person-years in pediatric controls was 0.06 
(95% CI 0.02–0.15) compared to 1.5 (95% CI 0.6–4.1) in all pediatric cancers, 0.9 (95% CI 0.1–6.1) 
in leukemia/lymphoma, 8.1 (95% CI 2.0–33.0) in soft tissue sarcoma/bone tumors, and 4.0 (95% CI 
0.6–29.0) in other sites. In this report, there was no reported VTE in children with brain tumors. 
Much of the literature in children with cancer focuses on patients with acute lymphoblastic leukemia 
(ALL), the most common pediatric malignancy. A meta-analysis of children with leukemia reported 
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VTE in 5.2% of children with ALL, but reported rates range from 
1 to 36% (13–15). VTE occurs in 7–16% of patients with soft tis-
sue sarcomas (16, 17). Interestingly, though thrombosis is often 
seen in adults with brain tumors, the incidence of thrombosis in 
children with brain tumors is quite low and ranges from <1 to 
2.8% (7, 18, 19).
The etiology of VTE in children with cancer is multifactorial 
and includes genetic predisposition (thrombophilia), disease-
related factors, and treatment-related factors including use 
of CVC, surgery, and chemotherapy. A Canadian multicenter 
case–control study of children with cancer identified age (≤2 and 
>10 years), blood group (non-O), and use of l-asparaginase as 
independent risk factors for DVT occurrence (20).
Cancer may be considered a hypercoagulable state. Albayrak 
et  al. found activated coagulation and reduced fibrinolysis in 
children with ALL prior to chemotherapy (21). Giordano et al. 
identified thrombin generation at ALL diagnosis (22). The patho-
physiology of this hypercoagulable state is related to secretion 
of cytokines and clotting factors by cancer cells (23). Pediatric 
tumors with mass effect impair blood flow and increase risk of 
VTE. In children with lymphoma, the presence of a mediastinal 
mass, which compresses upper extremity veins, increases the risk 
of thrombosis (24). Renal tumors with vascular invasion are also 
associated with VTE.
The majority of children with cancer have CVC placed for 
administration of chemotherapy and other supportive care. CVC 
is the most common risk factor for VTE in children with cancer. 
Reported rates of symptomatic catheter-related VTE range from 
2.6 to 36.7%, and rates of asymptomatic catheter-related VTE 
range from 5.9 to 43% (25–27).
Certain aspects of cancer treatment increase the risk of 
thrombosis. Giordano et al. prospectively monitored changes in 
the coagulation parameters of children with ALL and showed that 
treatment for ALL altered the quantity and activity of numerous 
hemostatic proteins (22).
l-Asparaginase, which is used for treatment of ALL, is a well 
described risk factor for VTE. l-Asparaginase has widespread 
effects on coagulation including reduction in antithrombin. 
Steroids (particularly prednisone) increase factor VIII von 
Willebrand factor, which contributes to prothrombotic risk (23, 
28, 29).
Additional prothrombotic risk factors include catheter-related 
blood stream and other infections in the immunocompromised 
patients as well as immobility during hospitalization, particularly 
in the post-operative period.
VTE results in serious consequences, including death. In a 
meta-analysis of children with ALL who developed VTE, about 
half of events occurred in the central nervous system (CNS). 
Fifteen to twenty percent of CNS thrombosis results in long-term 
neurologic sequelae (30–32). The Nordic Society of Paediatric 
Haematology and Oncology followed 20 patients with ALL and 
cerebral sinus venous thrombosis (CSVT), two of whom had 
deaths attributed to CSVT (33). Post-thrombotic syndrome 
(PTS), a chronic complication of VTE associated with chronic 
leg swelling, pain, and sometimes skin changes including ulcera-
tion, complicates both symptomatic and asymptomatic VTE (34). 
Polen et al. conducted a prospective cohort study of children with 
a history of cancer after CVC removal. PTS occurred in 30.5–34% 
of patients depending on the method of diagnosis. A history of 
CVC occlusion, DVT, or multiple CVC placements was associ-
ated with PTS (35).
Treatment and Prevention of venous 
Thromboembolism in Children with 
Cancer
There are no specific guidelines for treatment of VTE in children 
with cancer. The anticoagulants most commonly used in children 
are warfarin and heparins (36). There are ongoing clinical trials 
of anticoagulants in pediatric oncology patients, but no results 
have been published. Clinicians must consider the increased risk 
of bleeding in oncology patients who have thrombocytopenia and 
either withhold anticoagulation at low platelet counts or transfuse 
platelets at a lower threshold.
Thromboprophylaxis guidelines are well established for adults 
with cancer (37, 38). No such guidelines exist for children, even 
for those without cancer. There are limited data on prophylactic 
strategies of warfarin, low-molecular-weight heparin (LMWH), 
and antithrombin replacement in pediatric oncology patients with 
ALL (26, 39–46). None of these studies resulted in evidence-based 
strategies to prevent thrombosis. Nowak-Göttl et al. conducted 
an uncontrolled study of prophylaxis with LMWH in children 
with sarcomas; none developed VTE (47).
Several investigators have developed risk prediction models. 
Mitchell et  al. published a validated, predictive model for the 
development of VTE in patients with ALL, which may be adapted 
to local patient population and practice to prevent VTE (43, 48). 
Bell et  al. also published an approach to risk assessment and 
prophylaxis in this population (49). The Italian Association of 
Pediatric Hematology and Oncology made recommendations 
specifically for prolonged use of CVC in children with cancer 
and blood disorders. They recommend insertion of the CVC on 
the right side of the upper venous system and also the placing of 
the tip of the CVC at the right atrial–superior vena cava junc-
tion (50). These recommendations are based on studies showing 
higher rates of thrombosis when CVCs were placed on the left 
side and not placed at the right atrial–superior vena cava junction 
(51, 52).
Summary
Children with cancer are at risk for developing VTE secondary 
to disease- and treatment-related factors and other inherited and 
acquired conditions. However, there is still much to be learned 
regarding risk factors, prevention, and treatment of VTE in this 
population.
vTe in CHiLDRen wiTH BLOOD 
DiSORDeRS
VTE has been reported in children with acquired and inherited 
blood disorders. VTE occurs secondary to a combination of 
(1) underlying disease pathophysiology; (2) complications of 
disease; and (3) treatment of disease including medication, CVC 
placement, and surgery. See Table 1.
TABLe 1 | Risk factors for venous thromboembolism in children with 
cancer and blood disorders.
Cancera Sickle cell anemiaa Hemophilia
Central 
venous 
catheter
Chemotherapy Chronic blood 
transfusions
Prophylaxis
Supportive Care Erythrocytapheresis Immune 
tolerance 
induction
Surgery Surgical management 
of cancer
Splenectomyb Orthopedic 
proceduresCholecystectomy
Orthopedic procedures
Immobility 
due to pain
Cancer and treatment-
related pain
Vaso-occlusive pain 
crisis
Joint or muscle 
hemarthrosis
Avascular necrosis Chronic 
arthropathy
Infection Sepsis and other 
invasive infection 
secondary to 
immunocompromised 
state
Sepsis secondary 
to functional and/or 
surgical asplenia
Sepsis
Osteomyelitis
Acute chest syndrome
Medication Asparaginase Erythropoietin Factor 
replacement
Corticosteroids Bypassing 
agents
Erythropoietin
aUnderlying disorder is associated with hypercoaguability.
bPostsplenectomy state is associated with increased risk of VTE.
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A number of blood disorders are associated with inherent 
hypercoagulable states including [sickle cell anemia (SCA), see 
below]; vascular malformations (disseminated intravascular 
coagulation); hemophagocytic lymphohistiocytosis (hyper-
inflammatory state); immune thrombocytopenic purpura (ITP); 
and autoimmune hemolytic anemia (AIHA) (53). Management 
of blood disorders with splenectomy is noteworthy, because the 
postsplenectomy state is associated with increased risk for VTE 
(54, 55). Splenectomy is indicated in children with SCA who suf-
fer recurrent splenic sequestration and hypersplenism. Children 
with thalassemia may undergo splenectomy to increase red cell 
survival and decrease transfusion requirements. Splenectomy 
is an alternative to medical management in some cases of ITP, 
AIHA, and hereditary spherocytosis.
The rest of this section will focus on VTE in SCA and 
hemophilia.
vTe in SCA
Sickle cell anemia is a hemoglobinopathy characterized by the 
presence of hemoglobin S. Clinical manifestations result from red 
cell hemolysis and vaso-occlusion. Acute complications include 
pain, acute chest syndrome (ACS), stroke, priapism, and splenic 
sequestration. Chronic complications include pulmonary hyper-
tension, splenic dysfunction, and avascular necrosis (AVN).
Data are sparse in regards to the rates of VTE in children with 
SCA. Primary data include case reports of VTE (56–59), case series 
of catheter-related thrombosis (see below), and data within larger 
adolescent and adult cohort studies. In the Cooperative Study of 
Sickle Cell Disease, including 1,523 patients aged ≥15 years, the 
rate of first VTE was 5.2 per 1,000 person-years; including a PE 
rate of 3.6 per 1,000 person-years and isolated DVT rate of 1.6 
per 1,000 person-years. Then, 11.3% had a least one VTE by age 
40 years. Rates were highest in association with SS and Sβ0 thalas-
semia, and VTE was associated with higher risk of death.
Rates of VTE are expected to be higher than the general popu-
lation, because, in addition to the baseline prothrombotic state, 
children and adolescents with SCA have other disease-related 
risk factors for VTE. Of note, VTE occurs starting at a younger 
age in adults with SCA compared to African-American controls; 
in a study of hospitalized patients with SCA, the mean age of 
patients with PE was 28 years compared to 57 years in controls 
and the mean age of patients with DVT was 31 years in patients 
with SCA compared to 54 years in controls (60).
The coagulation system is activated in SCA and SCA may be 
considered as a hypercoagulable state with higher levels of platelet 
activation, thrombin generation, and inflammation (61–66). 
Anticoagulants and antiplatelet agents are being studied as novel 
therapeutic agents for prevention complications in SCA (67).
The most common risk factor for VTE in children with SCA is 
presence of a CVC. CVC may be placed for short- and long-term 
venous access (68–71). A temporary CVC may be placed acutely 
during hospitalization for individuals with poor venous access, 
who are acutely ill and require intensive care, or in individuals 
with poor venous access requiring prolonged duration of intrave-
nous therapy. Apheresis catheters are placed to facilitate exchange 
transfusion in the setting of stroke or ACS. Single or double 
lumen CVC is inserted to facilitate chronic red cell transfusions or 
exchange transfusion for primary and secondary stroke preven-
tion (72). Jeng et al. reported a rate of catheter-related thrombosis 
of 0.99 per 1,000 catheter days in patients aged 1.4–30 years; 33% 
of the reported patients had catheter-related thrombosis (69). 
Shah et al. reported a rate of catheter-related thrombosis of 0.49 
per 1,000 catheter days in patients aged 1–59 years; 41% of the 
reported patients had catheter-related thrombosis (68).
Other acquired prothrombotic risk factors in SCA include 
obesity, immobility, infection, and splenectomy. Although 
growth failure is a concern in children with SCA, rates of obesity, 
a known risk factor for VTE, are rising in children with SCA (73). 
Individuals with SCA may have chronic or acute immobility. 
Chronic immobility is related to chronic pain including pain from 
AVN. Acute immobility occurs during hospitalization for vaso-
occlusive pain and other sickle cell-related complications and at 
the time of surgery for surgical procedures including abdominal 
(i.e., splenectomy, cholecystectomy) and orthopedic procedures 
(i.e., core decompression). Children and adolescents are at risk 
for invasive infections due to functional asplenia. Infectious com-
plications include bacterial sepsis, ACS, and osteomyelitis. Other 
risk factors reported in adults with SCD SC and Sβ+ include 
higher hemoglobin and history or surgical splenectomy (74).
Clinicians must include VTE on the differential diagnosis 
of extremity and limb pain. If DVT occurs in the setting of 
vaso-occlusive crisis, diagnosis of DVT may be delayed if pain 
is attributed to vaso-occlusive crisis or other sickle cell-related 
complication. Chest pain occurring in hospitalized patients with 
SCA is most often attributed to vaso-occlusive crisis or ACS. PE 
must also be suspected in patients with significant chest pain 
and hypoxia. If PE is diagnosed, then extremity ultrasonography 
should be done to determine if thrombosis is truly embolic 
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or in  situ. Those with PE may be at higher risk for pulmonary 
hypertension (75).
d-Dimer is increased at baseline in SCA; therefore, d-dimer 
has lower prognostic significance in the diagnosis of VTE in SCA.
Treatment and Prevention of vTe in 
Children with SCA
There are no specific guidelines for treatment of VTE in patients 
with SCA. Guidelines for prevention of VTE in hospitalized 
pediatric patients are still under development. Even in the adult 
population, there are no disease specific recommendations for 
SCA. Clinicians who take care of children and adolescents with 
SCA should evaluate patients for acquired prothrombotic risk 
factors and consider thromboprophylaxis if multiple risk factors 
are present.
vTe in Children with Hemophilia
Although children with hemophilia are primarily at risk for 
bleeding and should be at lower risk of VTE due to clotting factor 
deficiency, thrombotic complications do occur. Thrombotic com-
plications in this population are most often attributed to CVC, 
clotting factor replacement, and disease-related complications.
Occurrence of vTe
Data are sparse on rates of thrombosis in children with hemo-
philia. Primary data include case reports and case series of 
children with catheter-related thrombosis.
As with SCA, CVC is the most common risk factor for VTE in 
children hemophilia. CVC is most often placed in children with 
hemophilia who require reliable venous access for prophylaxis, 
prophylactic clotting factor replacement administered one to 
four times per week, or immune tolerance induction, high-dose 
clotting factor administration up to 7 days per week for inhibitor 
eradication (76). Although Medeiros et  al. reported a low rate 
of catheter-related thrombosis in children with hemophilia (77), 
subsequent publications document asymptomatic and sympto-
matic catheter-related thrombosis in patients with hemophilia 
(78–81). Risk may increase with duration of catheter presence 
(81). Even asymptomatic VTE are important to recognize given 
the risk and morbidity of PTS (79, 80). Consensus recommenda-
tions for use of CVC in hemophilia include the following: use 
of the smallest possible catheter diameter, position the catheter 
tip in the lower third of the superior vena cava, evaluate for 
catheter-related thrombosis after 2–4  years, and transition to 
peripheral access as soon as possible if thrombosis is detected 
(82). In general, due to the risk of catheter-related thrombosis, 
CVC should be avoided when possible and removed as soon as 
peripheral venous access is reliable for factor administration.
Other acquired prothrombotic risk factors include obesity, 
immobility, orthopedic surgery, infection, and high doses of 
clotting factor replacement. Rates of overweight and obesity are 
high in hemophilia (83, 84). This may be related to restricted 
activities. Children with hemophilia may suffer acute immobil-
ity due to joint and muscle bleeds and less commonly chronic 
immobility due to hemophilic arthropathy. VTE in persons with 
hemophilia ≤18 years has been described in the setting of major 
orthopedic surgery (85, 86). Orthopedic procedures are less com-
mon in children with hemophilia than in adults. Nonetheless, if a 
pediatric patient with hemophilia undergoes a major orthopedic 
procedure then patient should be fully assessed for any additional 
risk factors for thrombosis such as obesity and preventive meas-
ures may be considered (87, 88). Children with hemophilia are 
not inherently immunocompromised but may have CVC-related 
infection or infection in the setting of immunomodulatory 
therapy for inhibitors.
Patients with hemophilia and inhibitors often require high and 
frequent doses of bypassing agents for treatment of bleeding and 
factor replacement for ITI. Silvey et al. described cases of PE in 
young children with hemophilia A and high-titer inhibitors (89). 
Girolami et al. also described a higher frequency of thrombosis 
in inhibitor patients (90).
The most common etiologies of swelling in the lower or upper 
extremities in children with hemophilia are hemarthrosis, intra-
muscular bleed, and soft tissue bleeds. Therefore, clinicians likely 
have a lower index of suspicion for VTE as a cause of swelling and 
pain in the extremities, and the diagnosis of VTE in this patient 
population may be missed or delayed. Despite the bleeding 
phenotype of hemophilia, clinicians should maintain an index of 
suspicion for VTE in children with inherited bleeding disorders 
who have multiple prothrombotic risk factors.
Treatment and Prevention of vTe in 
Children with Hemophilia
Martin and Key recently published an approach to treating 
patients with inherited bleeding disorders who need anticoagulant 
therapy (91). The authors point out that there are no standardized 
guidelines. When deciding whether or not to initiate anticoagula-
tion, the patient’s bleeding phenotype must be balanced against 
the risk of developing or not treating thrombosis. In some cases, 
prophylactic clotting factor to increase factor levels >30% and 
decrease risk of bleeding may be required to allow for safe anti-
coagulation. Short-acting and reversible therapeutic agents are 
favored due to higher risk of bleeding. The intensity and duration 
of therapy must be carefully considered to minimize bleeding 
outcomes while achieving desired anticoagulant outcome.
Summary
Children with blood disorders are at risk for VTE secondary 
due to disease-related factors, disease complications, and disease 
management. Care should be taken to target modifiable risk 
factors, to educate patients about signs and symptoms of VTE, 
and to consider thromboprophylaxis in the setting of multiple 
prothrombotic risk factors.
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